Segment & Geographic Data
Quant-Grade Normalized (live API)
API & CSV Delivery
Scynexis Inc's Business Segments
Scynexis Inc's reported revenue by business segment and by geographic region, quarterly and annual, normalized against the consolidated income statement. Free below: the top 3 rows per table, this quarter and this fiscal year. Subscriber access adds the full segment history and operating income by segment.
Segment Data As of FY
Reportable Segments
1
Largest Segment
License and Service
Total Revenue
$ 0
Regions Reported
-
Revenue Share by Reportable Segment - FY
- License and Service100%
Revenue by Reportable Segment - FY
| Segment | Revenue (Millions) | % of Total |
|---|---|---|
| License and Service | $ 0 | 100% |
Revenue by Product & Service Category - FY
- License and Service100%
Revenue by Product & Service Category - FY
| Category | Revenue (Millions) | % of Total |
|---|---|---|
| License and Service | $ 0 | 100% |
Product and service categories are a supplemental disclosure and are not required to sum to consolidated revenue or to the reportable segments above.
Annual Results
Revenue Share by Reportable Segment - FY
- License and Service100%
Revenue by Reportable Segment - FY
| Segment | Revenue (Millions) | % of Total |
|---|---|---|
| License and Service | $ 0 | 100% |
Description of Scynexis Inc
Scynexis Inc is a biotechnology company that focuses on developing and commercializing highly innovative therapies to address serious and life-threatening fungal infections. Founded in 2000 and headquartered in Jersey City, New Jersey, USA, Scynexis has an experienced leadership team that is dedicated to advancing medical science and improving the lives of patients worldwide.
Scynexis develops therapies for a wide range of fungal infections, including Candida and Aspergillosis, which are often associated with high morbidity and mortality rates. Their lead product candidate, ibrexafungerp (formerly SCY-078), is a novel antifungal drug that acts by inhibiting the fungal enzyme glucan synthase, which is required for the production of fungal cell walls. Ibrexafungerp has demonstrated that it can provide broad-spectrum activity against a range of fungal species and is expected to have a lower risk of developing drug resistance when compared to other available antifungal agents.
In addition to its lead product candidate, Scynexis has an extensive pipeline of antifungal products in development. They are exploring the potential of using ibrexafungerp to target other types of fungal infections, including those caused by drug-resistant strains. Also, Scynexis has developed a proprietary platform technology for the discovery and development of novel antifungal compounds, which they believe can significantly advance the treatment of severe fungal infections.
Scynexis has been successful in raising significant amounts of capital, enabling it to fund its operations and research activities. Moreover, they have established partnerships with reputable organizations, such as the National Institutes of Health (NIH), to advance their research and develop breakthrough treatments. Their partnerships also extend to commercialization deals with established pharmaceutical companies, such as Jiangsu Hengrui Medicine Co., Ltd. and IMMY Inc.
Overall, Scynexis is a pioneering biotechnology company that is dedicated to advancing the field of antifungal therapy. They aim to provide innovative, effective treatments to patients suffering from serious fungal infections and improve overall patient outcomes. Their commitment to scientific excellence and partnership collaborations make them a leader in the field of antifungal research and development.
Scynexis develops therapies for a wide range of fungal infections, including Candida and Aspergillosis, which are often associated with high morbidity and mortality rates. Their lead product candidate, ibrexafungerp (formerly SCY-078), is a novel antifungal drug that acts by inhibiting the fungal enzyme glucan synthase, which is required for the production of fungal cell walls. Ibrexafungerp has demonstrated that it can provide broad-spectrum activity against a range of fungal species and is expected to have a lower risk of developing drug resistance when compared to other available antifungal agents.
In addition to its lead product candidate, Scynexis has an extensive pipeline of antifungal products in development. They are exploring the potential of using ibrexafungerp to target other types of fungal infections, including those caused by drug-resistant strains. Also, Scynexis has developed a proprietary platform technology for the discovery and development of novel antifungal compounds, which they believe can significantly advance the treatment of severe fungal infections.
Scynexis has been successful in raising significant amounts of capital, enabling it to fund its operations and research activities. Moreover, they have established partnerships with reputable organizations, such as the National Institutes of Health (NIH), to advance their research and develop breakthrough treatments. Their partnerships also extend to commercialization deals with established pharmaceutical companies, such as Jiangsu Hengrui Medicine Co., Ltd. and IMMY Inc.
Overall, Scynexis is a pioneering biotechnology company that is dedicated to advancing the field of antifungal therapy. They aim to provide innovative, effective treatments to patients suffering from serious fungal infections and improve overall patient outcomes. Their commitment to scientific excellence and partnership collaborations make them a leader in the field of antifungal research and development.
Scynexis Inc is a biopharmaceutical company that focuses on developing and commercializing innovative anti-infective treatments, particularly targeting fungal infections. The company operates within various segments and offers a range of products and services aimed at addressing unmet medical needs in infectious disease therapeutics. Below is an extensive overview of its segments, products, and services.
Segments
1. Clinical Development:
- Scynexis has established itself in the field of clinical research, concentrating on the development of cutting-edge anti-infective therapies. The company primarily focuses on therapies for fungal infections, including difficult-to-treat conditions such as candidiasis and aspergillosis. Their clinical pipeline aims to address significant healthcare challenges posed by resistant strains of pathogens.
2. Commercialization:
- The company is dedicated to bringing its therapies to market in the United States and other international territories. Scynexis has a well-structured sales and marketing team that collaborates with healthcare providers, hospitals, and other stakeholders to ensure effective promotion and distribution of their products. This segment is vital for the successful adoption of their therapies in clinical practice.
Products and Services
1. Ibrexafungerp:
- As Scynexis’ lead product candidate, Ibrexafungerp is a groundbreaking oral antifungal medication intended for the treatment of a variety of fungal infections. It is particularly noteworthy for its efficacy against Candida and Aspergillus species, which are known for their challenging treatment landscapes. Ibrexafungerp has received Qualified Infectious Disease Product (QIDP) designation from the FDA, allowing for expedited development and review processes. The drug is in the late phases of clinical development, underscoring its potential to be a critical therapeutic option for patients with invasive candidiasis and invasive aspergillosis.
2. SCY-078:
- This investigational antifungal agent is currently in clinical trials and represents a novel treatment avenue for fungal infections, particularly those caused by resistant strains of Candida and Aspergillus. SCY-078 is being rigorously evaluated for its safety and effectiveness, contributing to Scynexis’ commitment to addressing the needs of patients suffering from serious fungal infections.
3. Contract Research Services:
- Scynexis offers a comprehensive suite of contract research services aimed at supporting other pharmaceutical companies and biotechnology firms in their own drug development endeavors. These services encompass drug discovery, preclinical testing, and clinical development, positioning Scynexis as a valuable partner in the biopharmaceutical landscape. Their expertise in anti-infectives also allows them to provide specialized services tailored to the unique challenges of developing infectious disease therapies.
4. Research Collaborations:
- The company actively engages in research partnerships with academic institutions and other pharmaceutical companies to foster innovation in anti-infective treatments. These collaborations facilitate the sharing of knowledge, resources, and expertise, driving advancements in the discovery and development of new therapies that aim to combat infectious diseases more effectively.
Summary
In conclusion, Scynexis Inc is a specialized biopharmaceutical company that excels in the research, development, and commercialization of novel anti-infective therapies. With a strong focus on addressing the pressing issues posed by fungal infections, the company boasts a robust product portfolio, including late-stage and experimental candidates, as well as an extensive range of services that supports the broader pharmaceutical ecosystem. By leveraging its expertise in clinical development and commercialization, Scynexis is well-positioned to contribute significantly to improving treatment options for patients with infectious diseases.
Segments
1. Clinical Development:
- Scynexis has established itself in the field of clinical research, concentrating on the development of cutting-edge anti-infective therapies. The company primarily focuses on therapies for fungal infections, including difficult-to-treat conditions such as candidiasis and aspergillosis. Their clinical pipeline aims to address significant healthcare challenges posed by resistant strains of pathogens.
2. Commercialization:
- The company is dedicated to bringing its therapies to market in the United States and other international territories. Scynexis has a well-structured sales and marketing team that collaborates with healthcare providers, hospitals, and other stakeholders to ensure effective promotion and distribution of their products. This segment is vital for the successful adoption of their therapies in clinical practice.
Products and Services
1. Ibrexafungerp:
- As Scynexis’ lead product candidate, Ibrexafungerp is a groundbreaking oral antifungal medication intended for the treatment of a variety of fungal infections. It is particularly noteworthy for its efficacy against Candida and Aspergillus species, which are known for their challenging treatment landscapes. Ibrexafungerp has received Qualified Infectious Disease Product (QIDP) designation from the FDA, allowing for expedited development and review processes. The drug is in the late phases of clinical development, underscoring its potential to be a critical therapeutic option for patients with invasive candidiasis and invasive aspergillosis.
2. SCY-078:
- This investigational antifungal agent is currently in clinical trials and represents a novel treatment avenue for fungal infections, particularly those caused by resistant strains of Candida and Aspergillus. SCY-078 is being rigorously evaluated for its safety and effectiveness, contributing to Scynexis’ commitment to addressing the needs of patients suffering from serious fungal infections.
3. Contract Research Services:
- Scynexis offers a comprehensive suite of contract research services aimed at supporting other pharmaceutical companies and biotechnology firms in their own drug development endeavors. These services encompass drug discovery, preclinical testing, and clinical development, positioning Scynexis as a valuable partner in the biopharmaceutical landscape. Their expertise in anti-infectives also allows them to provide specialized services tailored to the unique challenges of developing infectious disease therapies.
4. Research Collaborations:
- The company actively engages in research partnerships with academic institutions and other pharmaceutical companies to foster innovation in anti-infective treatments. These collaborations facilitate the sharing of knowledge, resources, and expertise, driving advancements in the discovery and development of new therapies that aim to combat infectious diseases more effectively.
Summary
In conclusion, Scynexis Inc is a specialized biopharmaceutical company that excels in the research, development, and commercialization of novel anti-infective therapies. With a strong focus on addressing the pressing issues posed by fungal infections, the company boasts a robust product portfolio, including late-stage and experimental candidates, as well as an extensive range of services that supports the broader pharmaceutical ecosystem. By leveraging its expertise in clinical development and commercialization, Scynexis is well-positioned to contribute significantly to improving treatment options for patients with infectious diseases.